Peter Dudek

Peter Dudek has over 13 years of experience in the life sciences industry spanning research, company building, corporate and traditional venture, across a broad range of therapeutic areas and modalities. He currently serves as President and Managing Partner of Merck’s MRL Ventures (MRLV) Fund and is responsible for its investments in Ambagon Therapeutics, Caraway Therapeutics, Carisma Therapeutics, HotSpot Therapeutics, InduPro Labs, LifeMine Therapeutics, Mozart Therapeutics, Photys Therapeutics and Tallac Therapeutics. Past board involvements include Imago Biosciences (NASDAQ: IMGO), Kymera Therapeutics (NASDAQ: KYMR), Lava Therapeutics (NASDAQ: LAVA), Tidal Therapeutics (sold to Sanofi) and Xilio Therapeutics (NASDAQ: XLO). Prior to MRLV, he was a Principal with Wellington Partners, a European venture fund with more than $1B under management. He has held roles at Entrepreneurs Fund and at the corporate venture arm of Novartis. Dr. Dudek received his B.Sc. with Honors from the University of British Columbia and was a research associate at the BC Centre for Disease Control. He obtained his Ph.D. from the University of Geneva and was a Postdoctoral Fellow at the University of Oxford.